Literature DB >> 28709704

Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.

Casey M Cosgrove1, David E Cohn1, Heather Hampel2, Wendy L Frankel3, Dan Jones3, Joseph P McElroy4, Adrian A Suarez3, Weiqiang Zhao3, Wei Chen3, Ritu Salani1, Larry J Copeland1, David M O'Malley1, Jeffrey M Fowler1, Ahmet Yilmaz3, Alexis S Chassen1, Rachel Pearlman2, Paul J Goodfellow5, Floor J Backes1.   

Abstract

OBJECTIVES: To determine the relationship between mismatch repair (MMR) classification and clinicopathologic features including tumor volume, and explore outcomes by MMR class in a contemporary cohort.
METHODS: Single institution cohort evaluating MMR classification for endometrial cancers (EC). MMR immunohistochemistry (IHC)±microsatellite instability (MSI) testing and reflex MLH1 methylation testing was performed. Tumors with MMR abnormalities by IHC or MSI and MLH1 methylation were classified as epigenetic MMR deficiency while those without MLH1 methylation were classified as probable MMR mutations. Clinicopathologic characteristics were analyzed.
RESULTS: 466 endometrial cancers were classified; 75% as MMR proficient, 20% epigenetic MMR defects, and 5% as probable MMR mutations. Epigenetic MMR defects were associated with advanced stage, higher grade, presence of lymphovascular space invasion, and older age. MMR class was significantly associated with tumor volume, an association not previously reported. The epigenetic MMR defect tumors median volume was 10,220mm3 compared to 3321mm3 and 2,846mm3, for MMR proficient and probable MMR mutations respectively (P<0.0001). Higher tumor volume was associated with lymph node involvement. Endometrioid EC cases with epigenetic MMR defects had significantly reduced recurrence-free survival (RFS). Among advanced stage (III/IV) endometrioid EC the epigenetic MMR defect group was more likely to recur compared to the MMR proficient group (47.7% vs 3.4%) despite receiving similar adjuvant therapy. In contrast, there was no difference in the number of early stage recurrences for the different MMR classes.
CONCLUSIONS: MMR testing that includes MLH1 methylation analysis defines a subset of tumors that have worse prognostic features and reduced RFS.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  DNA mismatch repair; Endometrial cancer; Epigenomics; Lymph node excision; Lynch syndrome

Mesh:

Substances:

Year:  2017        PMID: 28709704      PMCID: PMC5601318          DOI: 10.1016/j.ygyno.2017.07.003

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  37 in total

1.  Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.

Authors:  M K McConechy; A Talhouk; H H Li-Chang; S Leung; D G Huntsman; C B Gilks; J N McAlpine
Journal:  Gynecol Oncol       Date:  2015-01-28       Impact factor: 5.482

2.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset.

Authors:  Heather Hampel; Julie A Stephens; Eero Pukkala; Risto Sankila; Lauri A Aaltonen; Jukka-Pekka Mecklin; Albert de la Chapelle
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

3.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.

Authors:  Heather Hampel; Wendy Frankel; Jenny Panescu; Janet Lockman; Kaisa Sotamaa; Daniel Fix; Ilene Comeras; Jennifer La Jeunesse; Hidewaki Nakagawa; Judith A Westman; Thomas W Prior; Mark Clendenning; Pamela Penzone; Janet Lombardi; Patti Dunn; David E Cohn; Larry Copeland; Lynne Eaton; Jeffrey Fowler; George Lewandowski; Luis Vaccarello; Jeffrey Bell; Gary Reid; Albert de la Chapelle
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.

Authors:  G Strathdee; M J MacKean; M Illand; R Brown
Journal:  Oncogene       Date:  1999-04-08       Impact factor: 9.867

5.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

6.  Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.

Authors:  Floor J Backes; Marino E Leon; Iouri Ivanov; Adrian Suarez; Wendy L Frankel; Heather Hampel; Jeffrey M Fowler; Larry J Copeland; David M O'Malley; David E Cohn
Journal:  Gynecol Oncol       Date:  2009-06-10       Impact factor: 5.482

7.  Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma.

Authors:  Destin Black; Robert A Soslow; Douglas A Levine; Carmen Tornos; Shirley C Chen; Amanda J Hummer; Faina Bogomolniy; Narciso Olvera; Richard R Barakat; Jeff Boyd
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

8.  Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.

Authors:  Israel Zighelboim; Paul J Goodfellow; Feng Gao; Randall K Gibb; Matthew A Powell; Janet S Rader; David G Mutch
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

9.  Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.

Authors:  Rachel Pearlman; Wendy L Frankel; Benjamin Swanson; Weiqiang Zhao; Ahmet Yilmaz; Kristin Miller; Jason Bacher; Christopher Bigley; Lori Nelsen; Paul J Goodfellow; Richard M Goldberg; Electra Paskett; Peter G Shields; Jo L Freudenheim; Peter P Stanich; Ilene Lattimer; Mark Arnold; Sandya Liyanarachchi; Matthew Kalady; Brandie Heald; Carla Greenwood; Ian Paquette; Marla Prues; David J Draper; Carolyn Lindeman; J Philip Kuebler; Kelly Reynolds; Joanna M Brell; Amy A Shaper; Sameer Mahesh; Nicole Buie; Kisa Weeman; Kristin Shine; Mitchell Haut; Joan Edwards; Shyamal Bastola; Karen Wickham; Karamjit S Khanduja; Rosemary Zacks; Colin C Pritchard; Brian H Shirts; Angela Jacobson; Brian Allen; Albert de la Chapelle; Heather Hampel
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

10.  Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.

Authors:  Paul J Goodfellow; Caroline C Billingsley; Heather A Lankes; Shamshad Ali; David E Cohn; Russell J Broaddus; Nilsa Ramirez; Colin C Pritchard; Heather Hampel; Alexis S Chassen; Luke V Simmons; Amy P Schmidt; Feng Gao; Louise A Brinton; Floor Backes; Lisa M Landrum; Melissa A Geller; Paul A DiSilvestro; Michael L Pearl; Shashikant B Lele; Matthew A Powell; Richard J Zaino; David Mutch
Journal:  J Clin Oncol       Date:  2015-11-09       Impact factor: 44.544

View more
  22 in total

1.  EBV infection is associated with histone bivalent switch modifications in squamous epithelial cells.

Authors:  Merrin Man Long Leong; Arthur Kwok Leung Cheung; Wei Dai; Sai Wah Tsao; Chi Man Tsang; Christopher W Dawson; Josephine Mun Yee Ko; Maria Li Lung
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

2.  Protons and High-Linear Energy Transfer Radiation Induce Genetically Similar Lymphomas With High Penetrance in a Mouse Model of the Aging Human Hematopoietic System.

Authors:  Rutulkumar Patel; Luchang Zhang; Amar Desai; Mark J Hoenerhoff; Lucy H Kennedy; Tomas Radivoyevitch; Chiara La Tessa; Stanton L Gerson; Scott M Welford
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-07-04       Impact factor: 7.038

3.  Microsatellite instability in endometrial cancer: New purpose for an old test.

Authors:  Katherine C Kurnit; Shannon N Westin; Robert L Coleman
Journal:  Cancer       Date:  2019-03-26       Impact factor: 6.860

4.  Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer.

Authors:  Karen A Cadoo; Diana L Mandelker; Semanti Mukherjee; Carolyn Stewart; Deborah DeLair; Vignesh Ravichandran; Preethi Srinivasan; Daire Hurley; Yelena Kemel; Angela G Arnold; Margaret Sheehan; Nisha Pradhan; Vijai Joseph; Dennis S Chi; Ginger J Gardner; Elizabeth L Jewell; Mario M Leitao; Kara Long Roche; Jennifer J Mueller; Yukio Sonoda; Oliver Zivanovic; Michael Walsh; Maria I Carlo; Michael F Berger; David Hyman; Liying Zhang; Mark E Robson; Kenneth Offit; Carol Aghajanian; Nadeem R Abu Rustum; Zsofia Stadler
Journal:  JCO Precis Oncol       Date:  2019-04-25

Review 5.  Adjuvant chemotherapy in endometrial cancer.

Authors:  César Gómez-Raposo; María Merino Salvador; Cristina Aguayo Zamora; Enrique Casado Saenz
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-16       Impact factor: 3.333

Review 6.  The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy?

Authors:  Mohamed Laban; Seif Tarek El-Swaify; Sara H Ali; Mazen A Refaat; Mohamed Sabbour; Nourhan Farrag; Alaa Sayed Hassanin
Journal:  Reprod Sci       Date:  2021-04-15       Impact factor: 3.060

Review 7.  Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers.

Authors:  Casey M Cosgrove; David Barrington; Floor J Backes
Journal:  Curr Oncol Rep       Date:  2021-05-03       Impact factor: 5.075

Review 8.  Clinical actionability of molecular targets in endometrial cancer.

Authors:  Mary Ellen Urick; Daphne W Bell
Journal:  Nat Rev Cancer       Date:  2019-08-06       Impact factor: 60.716

9.  Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.

Authors:  Annukka Pasanen; Mikko Loukovaara; Ralf Bützow
Journal:  Mod Pathol       Date:  2020-02-14       Impact factor: 7.842

10.  Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.

Authors:  David A Wheeler; Naoko Takebe; Toshinori Hinoue; Katherine A Hoadley; Maria F Cardenas; Alina M Hamilton; Peter W Laird; Linghua Wang; Adrienne Johnson; Ninad Dewal; Vincent Miller; David Piñeyro; Manuel Castro de Moura; Manel Esteller; Hui Shen; Jean Claude Zenklusen; Roy Tarnuzzer; Lisa M McShane; James V Tricoli; Paul M Williams; Irina Lubensky; Geraldine O'Sullivan-Coyne; Elise C Kohn; Richard F Little; Jeffrey White; Shakun Malik; Lyndsay Harris; Carol Weil; Alice P Chen; Chris Karlovich; Brian Rodgers; Lalitha Shankar; Paula Jacobs; Tracy Nolan; Jianhong Hu; Donna M Muzny; Harshavardhan Doddapaneni; Viktoriya Korchina; Julie Gastier-Foster; Jay Bowen; Kristen Leraas; Elijah F Edmondson; James H Doroshow; Barbara A Conley; S Percy Ivy; Louis M Staudt
Journal:  Cancer Cell       Date:  2020-11-19       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.